TY - JOUR
T1 - Gene and miRNA expression in giant cell arteritis-a concise systematic review of significantly modified studies
AU - Kuret, Tadeja
AU - Burja, Blaž
AU - Feichtinger, Julia
AU - Thallinger, Gerhard G
AU - Frank-Bertoncelj, Mojca
AU - Lakota, Katja
AU - Žigon, Polona
AU - Sodin-Semrl, Snezna
AU - Čučnik, Saša
AU - Tomšič, Matija
AU - Hočevar, Alojzija
PY - 2019/2
Y1 - 2019/2
N2 - Giant cell arteritis (GCA) is a systemic vasculitis in individuals older than 50 years, characterized by headaches, visual disturbances, painful scalp, jaw claudication, impairment of limb arteries, and systemic inflammation, among other symptoms. GCA diagnosis is confirmed by a positive temporal artery biopsy (TAB) or by imaging modalities. A prominent acute phase response with inflammation is the hallmark of the disease, predominantly targeting large- and medium-sized arteries leading to stenosis or occlusion of arterial lumen. To date, there are no reliable tissue markers specific for GCA. Scarce reports have indicated the importance of epigenetics in GCA. The current systematic review reports significantly changed candidate biomarkers in TABs of GCA patients compared to non-GCA patients using qPCR.
AB - Giant cell arteritis (GCA) is a systemic vasculitis in individuals older than 50 years, characterized by headaches, visual disturbances, painful scalp, jaw claudication, impairment of limb arteries, and systemic inflammation, among other symptoms. GCA diagnosis is confirmed by a positive temporal artery biopsy (TAB) or by imaging modalities. A prominent acute phase response with inflammation is the hallmark of the disease, predominantly targeting large- and medium-sized arteries leading to stenosis or occlusion of arterial lumen. To date, there are no reliable tissue markers specific for GCA. Scarce reports have indicated the importance of epigenetics in GCA. The current systematic review reports significantly changed candidate biomarkers in TABs of GCA patients compared to non-GCA patients using qPCR.
U2 - 10.1007/s10067-018-4231-y
DO - 10.1007/s10067-018-4231-y
M3 - Article
C2 - 30069799
VL - 38
SP - 307
EP - 316
JO - Clinical Rheumatology
JF - Clinical Rheumatology
SN - 0770-3198
IS - 2
ER -